Researchers Identify Novel Therapeutic Strategy for Rett Syndrome Through Alternative Splicing Modulation
核心洞察
Researchers at Texas Children's Duncan Neurological Research Institute (搜索) and Baylor College of Medicine have discovered a potential new treatment approach for Rett syndrome (搜索) by modulating alternative splicing of the MECP2 (搜索) gene.
The strategy involves blocking production of the MeCP2 (搜索)-E2 protein variant to increase levels of the functional MeCP2-E1 protein, achieving 50-60% increases in protein abundance in mouse models.
Preclinical studies using patient-derived cells showed that this approach restored normal cellular structure, electrical activity, and gene regulation capabilities depending on mutation severity.
Researchers at Texas Children's Duncan Neurological Research Institute (搜索) and Baylor College of Medicine have identified a promising new therapeutic strategy for Rett syndrome (搜索), a rare neurodevelopmental disorder that currently has no cure. The approach, published in Science Translational Medicine, targets the alternative splicing of the MECP2 (搜索) gene to increase levels of functional protein in affected patients.
Rett syndrome (搜索) is a rare genetic neurodevelopmental condition that causes developmental regression, typically after 6 to 18 months of normal growth, leading to severe impairments in motor skills, speech and communication. The disorder primarily affects girls, occurring in about 1 in 10,000 live births, according to corresponding author Dr. Huda Zoghbi, director of the Duncan NRI and Distinguished Service Professor at Baylor.
Understanding the Molecular Basis
The syndrome is caused by loss-of-function mutations in the MECP2 (搜索) gene, which is essential for normal brain function as it modulates the levels of several genes regulating neurological functions. These mutations either lead to loss of the protein or encode a defective protein that cannot fulfill its normal function. Approximately 65% of patients with Rett syndrome (搜索) have partially functional MeCP2 proteins that either have decreased DNA binding or are less abundant than normal.
Mouse models have demonstrated that Rett syndrome (搜索) is reversible - introducing normal MeCP2 (搜索) protein in the brains of affected mice reverses the symptoms. Importantly, researchers have shown that increasing the levels of a mutant MeCP2 protein that retains some function also improves symptoms, including survival, motor coordination and respiratory abnormalities in mice.
Novel Therapeutic Approach
The research team discovered that the brain normally produces two slightly different versions of the MeCP2 (搜索) protein, known as E1 and E2, which come from the same gene processed in different ways. The MeCP2-E1 protein uses ingredients e1, e3 and e4, while MeCP2-E2 combines all four ingredients (e1, e2, e3 and e4), making ingredient e2 unique to this version. The brain produces both versions, but E1 predominates.
Crucially, the researchers noted that there have been no reports of Rett syndrome (搜索) patients carrying mutations on the E2 protein - only mutations that disrupt E1 protein cause the condition. This observation led to the hypothesis that guiding brain cells to skip the e2 ingredient would promote the production of more MeCP2 (搜索)-E1 protein in patients with Rett syndrome and improve disease outcomes.
Preclinical Validation
The research team first genetically deleted ingredient e2 from the normal Mecp2 (搜索) gene in mice and assessed the effect on protein abundance and neurological function. "We were pleased to find that this approach led to 50% to 60% increase of MeCP2 protein in normal mice," said first author Harini Tirumala, graduate student of molecular and human genetics in the Zoghbi lab.
The researchers then applied the same approach to cells derived from patients with Rett syndrome (搜索) carrying MECP2 (搜索) mutations that reduce protein abundance and activity. After deleting ingredient e2 from the mutant MECP2 gene, they found that this enhanced MeCP2 production. "Importantly, depending on the severity of the mutation, these cells recovered part or all of their normal structure, their normal electrical activity and their ability to regulate the levels of other genes," Tirumala explained.
Therapeutic Potential
To assess the drug development potential of this approach, the team tested morpholinos (搜索) - synthetic molecules designed to prevent the production of MeCP2 (搜索)-E2 protein by blocking access to the e2 ingredient. The morpholinos significantly increased MeCP2 protein levels in mice, demonstrating the therapeutic viability of the concept.
"Our work lays the foundation and provides preclinical evidence for a therapeutic approach for Rett syndrome (搜索) that increases MeCP2 (搜索) and confers functional improvement," Zoghbi said. While morpholinos (搜索) themselves are not suitable due to toxicity concerns, similar strategies like antisense oligonucleotide therapies already used in other conditions could potentially be developed for Rett syndrome.
The challenge in developing MeCP2 (搜索)-targeting therapeutics lies in achieving the right balance - too little MeCP2 causes Rett syndrome (搜索), while too much causes MECP2 Duplication Syndrome (搜索), a different neurological disorder. This delicate balance has made it challenging to develop safe and effective treatments until now.
The study provides proof of concept that increasing the levels of mutant MeCP2 (搜索) in patients with the condition could provide therapeutic benefit, offering new hope for families affected by this devastating disorder. The research was funded by the National Institutes of Health, the Howard Hughes Medical Institute, and other organizations.